01.31.19
Michal Ayalon, Ph.D., has been appointed vice president of R&D, Kamada Ltd. Dr. Ayalon has 20 years of experience in drug discovery and drug development, including non-clinical and clinical development, manufacturing and control, regulatory, and project management. She will oversee all of Kamada's R&D and IP activities, and report directly to Amir London, Kamada’s chief executive officer. Dr. Ayalon succeeds Liliana Bar, Ph.D. who has served as Kamada’s VP R&D since 2012 and is retiring.
Dr. Ayalon previously served as head of R&D at 89bio Ltd., where she led the overall development strategy of the company and managed all R&D functions, including medical, clinical, preclinical, CMC, regulatory, and project management. Dr. Ayalon was also a Project Champion at Teva Pharmaceutical Industries, where she led novel biologics and biosimilar projects in oncology, respiratory and metabolic disease, and vice president of R&D at Galmed Pharmaceuticals Ltd.
“We are excited to have Michal join the Kamada executive team as we begin 2019,” said Mr. London. “Michal’s comprehensive knowledge and understanding of drug development from drug discovery and early-stage research all the way through advanced clinical programs will be of significant value to Kamada as we continue developing our robust pipeline. I would like to also take this opportunity to thank Liliana Bar for her significant contribution to Kamada leading our R&D and IP activities during recent years.”
Dr. Ayalon previously served as head of R&D at 89bio Ltd., where she led the overall development strategy of the company and managed all R&D functions, including medical, clinical, preclinical, CMC, regulatory, and project management. Dr. Ayalon was also a Project Champion at Teva Pharmaceutical Industries, where she led novel biologics and biosimilar projects in oncology, respiratory and metabolic disease, and vice president of R&D at Galmed Pharmaceuticals Ltd.
“We are excited to have Michal join the Kamada executive team as we begin 2019,” said Mr. London. “Michal’s comprehensive knowledge and understanding of drug development from drug discovery and early-stage research all the way through advanced clinical programs will be of significant value to Kamada as we continue developing our robust pipeline. I would like to also take this opportunity to thank Liliana Bar for her significant contribution to Kamada leading our R&D and IP activities during recent years.”
